PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
08-Jun-2022 First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD) HMNC Brain Health
08-Jun-2022 Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial AstraZeneca
07-Jun-2022 SCRS Global Impact Partner Program Grows with Addition of Clinerion Clinerion Ltd.
07-Jun-2022 Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus Arbutus Biopharma Corporation
07-Jun-2022 Nouscom Announces Positive Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Immunotherapy for the Treatment of dMMR / MSI-H Solid Tumors, at ASCO 2022 Nouscom
07-Jun-2022 Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 Transgene
07-Jun-2022 Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022 Enterome
07-Jun-2022 Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma Janssen
07-Jun-2022 Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment Nordic Nanovector
02-Jun-2022 Novotech Sponsors Pre-ASCO China Summit Panels on Early Phase Oncology Trials, Regulatory Strategy for China and US Novotech Health Holdings
01-Jun-2022 Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism Amolyt Pharma
01-Jun-2022 Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster Novavax
01-Jun-2022 Global Biosimilars and Follow-on Biologics R&D Market is projected to reach a market value of US$ 2,22,576.5 Million in 2031: Visiongain Research Inc Visiongain
01-Jun-2022 BIOCAPTIVA announces oversubscribed £2.1 million additional seed financing to complete first in human trial with the BioCaptis BIOCAPTIVA
31-May-2022 Update on Cialis® Rx-to-OTC Switch Actual Use Trial Sanofi
31-May-2022 US FDA accepts New Drug Application filed by Avillion for AstraZeneca’s PT027 for the as-needed treatment or prevention of symptoms in asthma patients AstraZeneca
30-May-2022 Global Single Cell Analysis Market is Projected to Grow at a CAGR of 15.1% By 2032 Visiongain
27-May-2022 First patients dosed in IRIS Phase III trial evaluating Saphnelo in lupus nephritis PUBLISHED27 May 2022 AstraZeneca
27-May-2022 Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 Oxford BioTherapeutics
27-May-2022 NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting NovalGen